Actually, I think in practice my solution is much simpler than yours. For yours to work it is a precondition that these audits are of good quality. Perhaps they

Actually, I think in practice my solution is much simpler than yours. For yours to work it is a precondition that these audits are of good quality. Perhaps they will be and perhaps not but at the very least we can note that the pharma companies have large incentives to game them. Also, the question becomes how much of a markup is reasonable. Clearly, for more innovative research more markup would be acceptable than for less innovative research if both of these would lead to working medicine. Innovativeness would need to be quantified for each and every medicine separately. This does not sound like an easy task. I really am surprised that I am getting more downvotes than upvotes here. I think people are too emotional about this. I also note that a post dropping f-bombs is not getting downvoted which it really should be. It is not very mature.